Literature DB >> 16781264

Review of medical abortion using mifepristone in combination with a prostaglandin analogue.

Christian Fiala1, Kristina Gemzel-Danielsson.   

Abstract

Induced abortion is still a major health problem in the world and the most frequently performed intervention in obstetrics and gynecology with an estimated total of 46 million worldwide each year. Medical abortion with mifepristone and prostaglandin was first introduced in 1988 and is now approved in 31 countries. This combination of drugs has recently been included in the List of Essential Medicines by the World Health Organisation. The present review summarizes the development, physiology and the development of the currently used regimens.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16781264     DOI： 10.1016/j.contraception.2006.03.018

Source DB:  PubMed          Journal:  Contraception        ISSN： 0010-7824            Impact factor:   3.375


  16 in total

1.  Opioid and progesterone signaling is obligatory for early human embryogenesis.

Authors:  Miguel J Gallego; Prashob Porayette; Maria M Kaltcheva; Sivan Vadakkadath Meethal; Craig S Atwood
Journal:  Stem Cells Dev       Date:  2009-06       Impact factor: 3.272

2.  The pregnancy hormones human chorionic gonadotropin and progesterone induce human embryonic stem cell proliferation and differentiation into neuroectodermal rosettes.

Authors:  Miguel J Gallego; Prashob Porayette; Maria M Kaltcheva; Richard L Bowen; Sivan Vadakkadath Meethal; Craig S Atwood
Journal:  Stem Cell Res Ther       Date:  2010-09-13       Impact factor: 6.832

3.  Uses of misoprostol in obstetrics and gynecology.

Authors:  Rebecca Allen; Barbara M O'Brien
Journal:  Rev Obstet Gynecol       Date:  2009

4.  Interferon-γ- and glucocorticoid-mediated pathways synergize to enhance death of CD4(+) CD8(+) thymocytes during Salmonella enterica serovar Typhimurium infection.

Authors:  Mukta Deobagkar-Lele; Suni K Chacko; Emmanuel S Victor; Jayachandra C Kadthur; Dipankar Nandi
Journal:  Immunology       Date:  2013-04       Impact factor: 7.397

5.  Development and in vitro/in vivo Evaluation of a Silastic Intravaginal Ring for Mifepristone Delivery.

Authors:  X Duan; M Ning
Journal:  Indian J Pharm Sci       Date:  2015 May-Jun       Impact factor: 0.975

6.  Does mode of follow-up influence contraceptive use after medical abortion in a low-resource setting? Secondary outcome analysis of a non-inferiority randomized controlled trial.

Authors:  Mandira Paul; Sharad D Iyengar; Birgitta Essén; Kristina Gemzell-Danielsson; Kirti Iyengar; Johan Bring; Marie Klingberg-Allvin
Journal:  BMC Public Health       Date:  2016-10-17       Impact factor: 3.295

7.  Two prophylactic medication approaches in addition to a pain control regimen for early medical abortion < 63 days' gestation with mifepristone and misoprostol: study protocol for a randomized, controlled trial.

Authors:  Monica V Dragoman; Daniel Grossman; Nathalie Kapp; Nguyen My Huong; Ndema Habib; Duong Lan Dung; Anand Tamang
Journal:  Reprod Health       Date:  2016-10-12       Impact factor: 3.223

8.  Early versus delayed insertion of intrauterine contraception after medical abortion - a randomized controlled trial.

Authors:  Ingrid Sääv; Olof Stephansson; Kristina Gemzell-Danielsson
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

9.  Pathway analysis for drug repositioning based on public database mining.

Authors:  Yongmei Pan; Tiejun Cheng; Yanli Wang; Stephen H Bryant
Journal:  J Chem Inf Model       Date:  2014-02-05       Impact factor: 4.956

10.  Expulsion and continuation rates after postabortion insertion of framed IUDs versus frameless IUDs - review of the literature.

Authors:  Dirk Wildemeersch; Norman D Goldstuck
Journal:  Open Access J Contracept       Date:  2015-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.